Nhasi TSC Alliance® inoombera mvumo yeUS Food and Drug Administration's (FDA's) yeHYFTOR™, inova yekutanga yakatenderwa neFDA kurapwa kweangiofibromas kumeso muvakuru nevana vane makore matanhatu kana kupfuura vane tuberous sclerosis complex (TSC) . HYFTOR ™, yakagadzirwa neNobelpharma America, LLC, ine Orphan Drug Status yeichi chiratidzo.
"TSC Alliance inogashira iyi nzira yekurapa yeangiofibromas," akadaro Kari Luther Rosbeck, Mutungamiriri & CEO weTSC Alliance. “Sezvo kazhinji kacho kachikanganisa chitarisiko chemunhu uye zvichikonzera kubuda ropa, kurapwa uku kune mukana wekunyatsodzikisa kukanganiswa kwechiratidzo ichi kuvanhu vakuru nevana vane TSC. Tinotenda kuzvipira kwaNobelpharma kunharaunda yeTSC. "
TSC chirwere chisina kujairika chemajini chinoita kuti mamota asiri ekenza aumbe panhengo dzakakosha, kusanganisira ganda. Angiofibromas inokonzerwa neTSC mapundu madiki anowanzo kupararira pachiso chepakati, kunyanya pamhino nematama, uye anowanzo kuungana mumikoto padivi pemhino. Angiofibromas kazhinji idiki pane peppercorn, asi inogona kukura yakakura. Vanogona kunge vane ruvara rweganda, pink kana tsvuku. Angiofibromas inowanikwa mune ruzhinji rwevanhu vane TSC pamusoro pemakore mashanu ezera uye vanogona kubuda ropa zviri nyore. Vanogona zvakare kuve nemhedzisiro yakaipa pakuonekwa uye kuzvidzora, zvichiita kuti vamwe vanhu vane TSC vadzivise magariro.
"Pamusangano weTSC Alliance's 2017 External-Led Patient-Focused Drug Development, takanzwa zvakananga kubva kune vanhu vane TSC kuti njodzi yekubuda ropa kumeso yakakanganisa sei kugona kwavo kutora chikamu mumitambo inoshanda," akadaro Steven L. Robards, PhD, Chief Scientific Officer we. TSC Alliance, "Tinovimba kuti chigadzirwa ichi chichabatsira vanhu vazhinji kurarama hupenyu hune hutano uye hunofadza."
ZVOKUBVA MUNYAYA INO:
- Angiofibromas caused by TSC are small bumps usually scattered on the central face, especially on the nose and cheeks, and are often clustered in the grooves at the side of the nose.
- “Since they often affect someone’s appearance and can cause bleeding, this treatment has the potential to truly reduce the impact of this manifestation on adults and children with TSC.
- Food and Drug Administration’s (FDA’s) approval of HYFTOR™, which is the first FDA-approved topical treatment for facial angiofibromas in adults and children six years of age or older who have tuberous sclerosis complex (TSC).
